Of these patients, 2 had complete loss of tumor CD19 and another had downregulation of CD19 with variable expression of other B-cell antigens [130] CAR-T cell expansion was noted in multiple patients, suggesting that there may have been T-cell-intrinsic causes of treatment failure. This evidence concerns the gene CD19 and neoplasm.